This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280)

This study has been terminated.
(Recruitment challenges.)
Integrated Therapeutics Group
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 7, 2003
Last updated: March 27, 2017
Last verified: March 2017
An association between seasonal allergic rhinitis (SAR) and allergic asthma has been established through epidemiologic, pathophysiologic, and therapeutic studies. This study will compare Nasonex Nasal Spray to Placebo in treating the nasal and asthma symptoms experienced by subjects with SAR and concomitant asthma.

Condition Intervention Phase
Rhinitis, Allergic, Seasonal Asthma Drug: Nasonex Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 188
Actual Study Start Date: April 3, 2003
Study Completion Date: November 26, 2003
Primary Completion Date: November 26, 2003 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   15 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Eligibility Criteria:

  • Subject must have at least a two-year history of seasonal allergic rhinitis and of increase asthma symptoms associated with the allergy season under study.
  • FEV 1 70% of predicted at both Screening and Baseline visits.
  • Subject must demonstrate an increase in absolute FEV 1 less then 12%, with an absolute volume increase of at least 200 ml, after reversibility testing at Screening or within the past 12 months.
  • Subjects must be skin test positive (skin prick test with a wheal diameter at least 3mm larger than the diluent control or intradermal testing with the wheal diameter at least 7 mm larger than diluent control) at screening, or within 12 months prior to the screening visit, to a seasonal allergen (which may include seasonal molds) prevalent during the study period.

Exclusion Criteria:

  • Subjects with asthma who require chronic use of inhaled or systemic corticosteroids.
  • Subjects who are morbidly obese (BMI>35)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Study Data/Documents: CSR Synopsis  This link exits the site

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00070707     History of Changes
Other Study ID Numbers: P03280
Study First Received: October 7, 2003
Last Updated: March 27, 2017

Keywords provided by Merck Sharp & Dohme Corp.:
Seasonal Allergic Rhinitis
Concomitant Asthma

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Nose Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents processed this record on June 23, 2017